In conclusion, under the treatment of DTX/omLip-HAR combined with HuR CRISPR, cell growth in TNBC cells and tumor-bearing mice was significantly reduced, and anticancer efficacy and safety were favorably increased in tumor-bearing mice. Here, ELAVL1 is linked to neoplasm.